291 related articles for article (PubMed ID: 15492262)
41. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia.
Nakao M; Yokota S; Horiike S; Taniwaki M; Kashima K; Sonoda Y; Koizumi S; Takaue Y; Matsushita T; Fujimoto T; Misawa S
Leukemia; 1996 Sep; 10(9):1463-70. PubMed ID: 8751464
[TBL] [Abstract][Full Text] [Related]
42. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1.
Pullarkat ST; Pullarkat V; Lagoo A; Brynes R; Weiss LM; Bedell V; Chen W; Huang Q; Gaal K; Weisenburger DD; Kim YS
Leuk Res; 2013 Nov; 37(11):1572-5. PubMed ID: 24035334
[TBL] [Abstract][Full Text] [Related]
43. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia.
Yamasaki H; Era T; Asou N; Sanada I; Matutes E; Yamaguchi K; Takatsuki K
Leukemia; 1995 Jul; 9(7):1147-53. PubMed ID: 7630188
[TBL] [Abstract][Full Text] [Related]
44. High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan.
Liang DC; Chou TB; Chen JS; Shurtleff SA; Rubnitz JE; Downing JR; Pui CH; Shih LY
Leukemia; 1996 Jun; 10(6):991-3. PubMed ID: 8667657
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.
Astsaturov IA; Matutes E; Morilla R; Seon BK; Mason DY; Farahat N; Catovsky D
Leukemia; 1996 May; 10(5):769-73. PubMed ID: 8656670
[TBL] [Abstract][Full Text] [Related]
46. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
47. Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia.
Maruyama F; Yang P; Stass SA; Cork A; Freireich EJ; Lee MS; Chang KS
Cancer Res; 1993 Oct; 53(19):4449-51. PubMed ID: 8402610
[TBL] [Abstract][Full Text] [Related]
48. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
[TBL] [Abstract][Full Text] [Related]
49. Variant translocation t(2;21;8)(q36;q22;q22) with RUNX1/CBFA2T1 (AML1/ETO) transcript in a case of acute myelogenous leukemia.
Hsiao HH; Sashida G; Kodama A; Fukutake K; Ohyashiki K
Cancer Genet Cytogenet; 2005 May; 159(1):96-7. PubMed ID: 15860366
[No Abstract] [Full Text] [Related]
50. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
[TBL] [Abstract][Full Text] [Related]
51. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
52. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.
Licht JD
Oncogene; 2001 Sep; 20(40):5660-79. PubMed ID: 11607817
[No Abstract] [Full Text] [Related]
53. Complex t(8;13;21)(q22;q14;q22)--a novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2).
Udayakumar AM; Alkindi S; Pathare AV; Raeburn JA
Arch Med Res; 2008 Feb; 39(2):252-6. PubMed ID: 18164974
[TBL] [Abstract][Full Text] [Related]
54. CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia.
Arber DA; Jenkins KA; Slovak ML
Am J Pathol; 1996 Oct; 149(4):1105-10. PubMed ID: 8863659
[TBL] [Abstract][Full Text] [Related]
55. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia.
Mikhail FM; Coignet L; Hatem N; Mourad ZI; Farawela HM; El Kaffash DM; Farahat N; Nucifora G
Genes Chromosomes Cancer; 2004 Feb; 39(2):110-8. PubMed ID: 14695990
[TBL] [Abstract][Full Text] [Related]
56. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
57. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
58. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
59. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker.
Torlakovic E; Torlakovic G; Nguyen PL; Brunning RD; Delabie J
Am J Surg Pathol; 2002 Oct; 26(10):1343-50. PubMed ID: 12360049
[TBL] [Abstract][Full Text] [Related]
60. Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.
Frater JL; Yaseen NR; Peterson LC; Tallman MS; Goolsby CL
Arch Pathol Lab Med; 2003 Mar; 127(3):356-9. PubMed ID: 12653584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
